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Regulation of multimers via truncated
isoforms: a novel mechanism to control
nitric-oxide signaling
Yuri Stasiv, Boris Kuzin, Michael Regulski, Tim Tully, and Grigori Enikolopov1
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA
Nitric oxide (NO) is an essential regulator of Drosophila development and physiology. We describe a novel
mode of regulation of NO synthase (NOS) function that uses endogenously produced truncated protein
isoforms of Drosophila NOS (DNOS). These isoforms inhibit NOS enzymatic activity in vitro and in vivo,
reflecting their ability to form complexes with the full-length DNOS protein (DNOS1). Truncated isoforms
suppress the antiproliferative action of DNOS1 in the eye imaginal disc by impacting the
retinoblastoma-dependent pathway, yielding hyperproliferative phenotypes in pupae and adult flies. Our
results indicate that endogenous products of the dNOS locus act as dominant negative regulators of NOS
activity during Drosophila development.
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Nitric oxide (NO) is produced in animal cells by NO
synthases (NOSs) in response to a wide range of diverse
stimuli. NO acts in an autocrine and paracrine fashion
on a large variety of cellular targets to initiate rapid and
transient, as well as slow and long-lasting physiological
changes (for review, see Ignarro 2000). In mammals,
these changes include blood-vessel relaxation, immune
response, cell cycle control, and neurotransmission. In
Drosophila, NO has been implicated in visual-system
development, immunity, behavior, response to hypoxia,
osmoregulation, and regulation of cell cycle progression
during development (Dow et al. 1994; Kuzin et al. 1996,
2000; Gibbs and Truman 1998; Wingrove and O’Farrell
1999; Nappi et al. 2000; DiGregorio et al. 2001; Teodoro
and O’Farrell 2003).
NO is a signaling molecule with diverse targets and
with limited spatial and temporal range. The potential of
NOS enzymes to trigger NO signaling cascades is re-
strained by an elaborate network of control mechanisms:
transcriptional, posttranscriptional, and translational
regulation; posttranslational modifications, such as
phosphorylation and palmitoylation; dependence on cal-
cium; subcellular localization; and interactions with
other proteins (Papapetropoulos et al. 1999; Wang et al.
1999a; Ignarro 2000; Nathan 2003). These modes of
regulation are not unique to the NOS-signaling sys-
tem; however, the complexity of the regulatory network
that controls production of NO makes this system an
attractive model for understanding how generation of a
signal is regulated in a physiological or developmental
context.
A potential mechanism for controlling NO action may
be related to the unusual complexity of the genomic or-
ganization of the NOS genes. For instance, more than 10
alternative promoters, in addition to multiple alterna-
tive splice sites and several polyadenylation sites are
used by mammalian neuronal NOS genes (Wang et al.
1999a). The choice of promoters, splice sites, and poly-
adenylation sites alters the coding capacity of NOS tran-
scripts as well as their translational efficiency (Wang et
al. 1999a,b). Likewise, the Drosophila NOS gene (dNOS)
encodes a family of at least 10 different transcripts that
may code for as many as seven different proteins
(Regulski and Tully 1995; Stasiv et al. 2001). Of these
mRNAs, which are generated through the use of alter-
native transcription initiation and splice sites, only one
isoform, dNOS1, encodes an enzymatically active pro-
tein, DNOS1. The majority of dNOS alternative tran-
scripts encode truncated proteins that lack the crucial
C-terminal reductase domain (with binding sites for
FMN, FAD, and NADPH) of the full-length DNOS1, but
retain the N-terminal oxygenase domain (with binding
sites for heme, L-arginine, and tetrahydro-L-biopterine).
All NO synthases are catalytically active as ho-
modimers; their oxygenase domains contain the active
center that oxidizes L-arginine to L-citrulline and NO,
whereas their reductase domains ensure the flow of elec-
trons required for the catalysis (Stuehr 1999; Alderton et
al. 2001). In NOS homodimers, the flow of electrons is
directed from the reductase domain of one polypeptide of
the dimer to the oxygenase domain of the other member
of the dimer (Siddhanta et al. 1998; Sagami et al. 2001).
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These structural features of NOS suggest a potential
regulatory mechanism that could use short NOS iso-
forms as inhibitors of the activity of the full-length pro-
tein. Given the structural similarities between various
isoforms of NOS across species, such mechanism could
be relevant both for Drosophila and for mammalian
NOSs; a number of reports describe alternative tran-
scripts that encode truncated NOS-like proteins (Wang
et al. 1999a). However, an experimental model to test
this hypothetical mechanism in vivo has not yet been
established; thus, the potential biological significance of
this notion has not yet been explored.
To understand how an inactive subunit of a multi-
meric protein may have a dominant negative effect on an
important signaling cascade in vivo, we focused on
DNOS4, a product of one of the more abundant alterna-
tive transcripts of the Drosophila NOS gene. We show
that DNOS4 is endogenously expressed in wild-type
Drosophila. We demonstrate that ectopic expression of
DNOS4 in the imaginal discs of Drosophila larvae sup-
presses the antiproliferative activity of DNOS1, result-
ing in hyperproliferative phenotypes in adult flies.
DNOS4 is able to form heterodimers with DNOS1 in
vitro and in vivo and inhibit production of NO. To-
gether, our results indicate that DNOS4 acts as an en-
dogenous dominant negative regulator of NOS activity
during Drosophila development, pointing to a novel
mechanism for the regulation of NO production.
Results
dNOS4 is an endogenous alternatively spliced
transcript of the Drosophila NOS gene
The dNOS locus of Drosophila is subject to complex
transcriptional and posttranscriptional regulation (Stasiv
et al. 2001). It produces a large variety of mRNA isoforms
through the use of multiple promoters and alternative
splice sites. Only one of them, dNOS1 (Fig. 1A), codes for
the full-length enzymatically active protein. Another
abundant alternative transcript of the dNOS gene is the
dNOS4 isoform, which retains the entire intron 13 (this
109-nucleotide-long segment is now referred to as exon
14a of dNOS4). The resulting open reading frame is ter-
minated by a stop codon 63 nucleotides into exon 14a
(Fig. 1A). It encodes a protein containing 757 amino acids
with a predicted molecular mass of 84 kDa (cf. DNOS1 is
1350 amino acids, 150 kDa). DNOS4 contains a unique
21-amino acid-long C-terminal peptide encoded by exon
14a, whereas the preceding 736 amino acids are identical
to those of DNOS1. Thus, the DNOS4 protein is a trun-
cated version of DNOS1; it lacks the entire reductase
domain, while retaining the oxygenase domain. Semi-
quantitative RT–PCR analysis indicates that dNOS4
mRNA is expressed in the embryo at levels comparable
to those of dNOS1 mRNA; dNOS4 levels are lower in
larvae and in adult flies, whereas dNOS1 levels do not
change appreciably (Fig. 1B).
Another variant of dNOS mRNA, dNOS7, encodes a
protein identical to DNOS4; however, the transcription
initiation site for dNOS7 RNA is different from that of
dNOS4 (exon 1a vs. exon 1b, respectively). Unlike
dNOS4, dNOS7 is exclusively expressed during the lar-
val stage (Stasiv et al. 2001).
Coexpression of DNOS1 and DNOS4 inhibits NOS
activity in vitro
DNOS4 lacks the C-terminal reductase domain that par-
ticipates in electron transfer during catalysis, while it
retains the catalytic N-terminal oxygenase domain, in-
Figure 1. Alternative splicing generates truncated DNOS isoforms. (A) The structure of two major dNOS transcripts, dNOS1 and
dNOS4. Regions encoding structural domains and cofactor-binding sites are shown. Exons are numbered and indicated by boxes (black
boxes for protein-coding regions, white boxes for 5- and 3-UTRs); gray shading highlights last 63 nucleotides (encoded by exon 14a)
of the dNOS4 open reading frame. (B) Expression of dNOS1, dNOS4, and actin 79B (taken as a control) transcripts throughout
Drosophila development. Total RNA samples were subjected to RT–PCR amplification using transcript-specific primers, followed by
Southern blot analysis. Sizes of amplified products are indicated.
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cluding the critical heme-binding site. DNOS4 also re-
tains a long stretch of glutamine (Gln) residues at the N
terminus; such regions have been shown to promote
multimerization of proteins (Perutz et al. 1994; Stott et
al. 1995; Zoghbi and Orr 2000; note that such Gln-rich
region is not present in mammalian NOS proteins).
These structural features of DNOS4 predict that (1)
DNOS4 itself is incapable of producing NO, (2) it may be
capable of forming heterodimers with DNOS1, and (3)
heteromers between DNOS1 and DNOS4 will have re-
duced enzymatic activity. To investigate whether
DNOS4 is capable of forming a heteromeric complex
with DNOS1 and suppressing NOS activity, and to ex-
amine which region of DNOS4 may contribute to its
effects on DNOS1, we used expression plasmids for
DNOS1 and DNOS4 proteins, each with a short peptide
tag fused to its C terminus (Fig. 2A), the influenza virus
hemagglutinin (HA) epitope-tagged DNOS1 (pDNOS1-
HA), and the synthetic FLAG epitope-tagged DNOS4
(pDNOS4-FLAG; Stasiv et al. 2001). We also generated a
plasmid, pDNOSoxy-FLAG, that codes for a shorter ver-
sion of DNOS4 (residues 214–631) and carries the FLAG
epitope at its C terminus (Fig. 2A). It lacks the Gln-rich
region at the N terminus, thus representing the “core”
oxygenase domain of DNOS, which is highly similar to
previously defined oxygenase domains of mammalian
NOS proteins (Regulski and Tully 1995; Raman et al.
1998; Fischmann et al. 1999).
To test the effect of DNOS4 and DNOSoxy proteins on
enzymatic activity of the full-length DNOS1, we tran-
siently coexpressed recombinant plasmids in cultured
human embryonic kidney cells (293 cells) and measured
NOS enzymatic activity in cell-free extracts. NOS activ-
ity was undetectable in lysates of untransfected cells and
in cells expressing either DNOS4-FLAG or DNOSoxy-
FLAG (data not shown), whereas lysates from cells trans-
fected with pDNOS1-HA showed significant levels of
NOS activity (Fig. 2B). In contrast, enzymatic activity in
cell lysates was decreased when a constant amount of
the pDNOS1-HA was cotransfected with increasing
amounts of the pDNOS4-FLAG. At a 1:1 molar ratio of
plasmids encoding DNOS4 and DNOS1, NOS activity
was 57% of the activity seen in lysates from cells trans-
fected by the plasmid encoding full-length DNOS1. At a
3:1 ratio, the activity dropped to 36%, and at 10:1 ratio it
was 10% of the control level (Fig. 2B). pDNOSoxy-FLAG,
which lacks both the reductase domain and the Gln-
rich region, was as effective at suppressing NOS activity
(13.5% of control levels when cotransfected with
pDNOS1-HA at 10:1 molar ratio) as pDNOS4-HA (which
retains the Gln-rich region). Importantly, expression lev-
els of DNOS1 protein were not affected by coexpressed
truncated DNOS variants, as determined by immuno-
blotting using HA-specific antibodies (Fig. 2B). This ob-
servation indicates that a decrease of NOS activity was
not simply due to a decrease in expression of the DNOS1
protein, but rather was caused by the presence of coex-
pressed shorter DNOS polypeptides. Furthermore, re-
moval of the Gln-rich region did not alter the inhibitory
effect of DNOSoxy on the enzymatic activity of DNOS1,
indicating that the Gln-rich stretch does not appreciably
contribute to the inhibitory action of DNOS4. Together,
these results indicate that truncated enzymatically inac-
tive forms of DNOS can suppress the activity of the full-
length DNOS1 protein, thereby acting as dominant nega-
tive inhibitors of NO production.
Direct interaction between DNOS1 and DNOS4
To examine the potential of DNOS1 and DNOS4 to form
complexes, we performed immunoprecipitation experi-
ments after coexpressing differentially tagged DNOS1
and DNOS4 in 293 cells. Each tagged DNOS protein was
immunoprecipitated from extracts of cotransfected cells
with antibody specific to its epitope tag (HA for DNOS1
or FLAG for DNOS4). Subsequently, the formation of
heteromeric DNOS complexes was examined by immu-
noblotting using HA-specific antibody for the samples
immunoprecipitated with FLAG-specific antibody and
vice versa.
When HA-tagged DNOS1 is expressed in 293 cells, it
can be immunoprecipitated with HA-specific but not
with FLAG-specific antibody (Fig. 2C). Conversely,
FLAG-tagged DNOS4 can be immunoprecipitated using
FLAG-specific, but not HA-specific antibodies. How-
ever, if DNOS1-HA and DNOS4-FLAG are coexpressed,
each of them can be immunoprecipitated by antibody to
either tag (Fig. 2C). Furthermore, when DNOSoxy-FLAG
was coexpressed with DNOS1-HA, complexes between
these two proteins were detected using the same combi-
nation of immunoprecipitation and immunoblotting
(Fig. 2C). This suggests that even a part of the oxygen-
ase domain lacking the Gln-rich region, but retaining
the heme-binding region, is sufficient to form hetero-
mers with the full-length DNOS1 protein. Finally, when
lysates of cells transfected separately with either
pDNOS1-HA or pDNOS4-FLAG were combined in vitro,
the two proteins did not coimmunoprecipitate with each
other (data not shown), indicating that heteromeric
DNOS complexes are not formed after cell lysis.
Together, these data point to a possible mechanism for
the observed dominant negative effect of DNOS4 on
DNOS1 activity, in which formation of DNOS1–DNOS4
heterodimers inhibits NOS activity by reducing forma-
tion of enzymatically active homodimers of DNOS1.
Ectopically expressed DNOS4 forms complexes with
DNOS1 and inhibits NOS activity in transgenic flies
To determine whether DNOS4 can act as a dominant
negative regulator of NOS activity in vivo, we generated
transgenic flies that express FLAG-tagged DNOS4 under
the control either of the heat-shock inducible promoter
of the hsp70 gene (hs-DNOS4-FLAG flies), or of the GMR
promoter, which is active in all cells of the eye imaginal
disc within, and posterior to the morphogenetic furrow
(GMR-DNOS4-FLAG flies). We confirmed that DNOS4-
FLAG was expressed in transgenic flies; anti-FLAG an-
tibodies detect a protein with an expected mass of 86
Stasiv et al.
1814 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on January 17, 2012 - Published by genesdev.cshlp.orgDownloaded from 
kDa in extracts from heads of GMR-DNOS4-FLAG and
from hs-DNOS4-FLAG flies, but not in extracts from
wild-type flies (Fig. 3A). The mobility of this protein was
identical to that of a protein produced in 293 cells after
transfection with pDNOS4-FLAG. Importantly, the ex-
pression levels of endogenously produced DNOS1 were
Figure 2. DNOS4 inhibits activity of the full-length DNOS1 enzyme in vitro. (A) DNOS proteins encoded by expression constructs
used for transient transfection of 293 cells. Structural domains are indicated. Cofactor-binding sites and the Gln-rich region are shown
by black boxes. Gray box indicates C-terminal peptide unique for DNOS4. HA or FLAG indicate epitope tags attached to C termini
of expressed DNOS proteins. The number of amino acid residues in each protein (excluding tags) is shown. (B) NOS activity in lysates
of transfected 293 cells. The pDNOS1-HA construct (DN1) was either expressed alone or coexpressed with indicated molar excess of
a truncated dNOS construct (either pDNOS4-FLAG [DN4] or pDNOSoxy-FLAG [DNoxy]). The total amount of DNA in each trans-
fection was kept constant by addition of carrier DNA. NOS activity was measured by the [3H]arginine–[3H]citrulline conversion assay.
Negligible NOS activity in lysates from cells transfected with the expression vector alone was subtracted from NOS activity detected
in experimental lysates. The activity data shown are expressed as a percentage of the NOS activity of the full-length enzyme alone
(14,330 cpm/min/mg total protein, 100% value). NOS activity in lysates from cells transfected with either pDNOS4-FLAG or
pDNOSoxy-FLAG construct alone was not detectable (data not shown). For the detection of expressed DNOS isoforms, an equal
amount of total protein (50 µg/lane) from cells transfected with different DNOS encoding constructs was analyzed by SDS-PAGE
followed by immunoblotting using either HA antibody of FLAG antibody. The results shown are representative of three independent
experiments; all data are mean ± standard error. Statistically significant differences (P < 0.05 according to Student’s t-test) between the
analyzed samples are marked with an asterisk (*). (C) DNOS4 forms heterodimers with the full-length DNOS1. Shown are the results
of coimmunoprecipitation of the full-length DNOS1-HA with truncated DNOS proteins tagged with FLAG epitope. Duplicate samples
of protein extracts (200 µg) from transfected 293 cells were immunoprecipitated either with the HA or FLAG antibody (indicated as
Ab for immunoprecipitation), followed by SDS-PAGE analysis and immunoblotting using either HA or FLAG antibody (indicated as
Ab for immunoblotting). “Transfected expression constructs” indicates dNOS expression constructs used in transfection experiments.
NOS regulation by dominant negative isoforms
GENES & DEVELOPMENT 1815
 Cold Spring Harbor Laboratory Press on January 17, 2012 - Published by genesdev.cshlp.orgDownloaded from 
not affected by ectopic expression of DNOS4 in trans-
genic flies (Fig. 3A). Furthermore, immunochemical de-
tection with FLAG-specific antibodies showed that
DNOS4-FLAG was expressed in the expected pattern
within, and posterior to the morphogenetic furrow in the
eye imaginal disc of third-instar GMR-DNOS4-FLAG
larvae (data not shown).
We next examined NOS activity in extracts from
heads of adult flies and found that in hs-DNOS4-FLAG
flies and in GMR-DNOS4-FLAG flies activity was 52%
and 60%, respectively, of that in control wild-type flies
(Fig. 3B). This indicates that endogenous NOS activity is
inhibited by ectopically expressed DNOS4, paralleling
observations with cultured cells.
To determine whether the observed decrease in NOS
activity in transgenic flies is accompanied by in vivo
formation of DNOS1–DNOS4 heterodimers, we per-
formed coimmunoprecipitation experiments. Using
FLAG-specific antibody, proteins were precipitated from
head extracts of adult wild-type or hs-DNOS4-FLAG
transgenic flies, and then were analyzed by immuno-
blotting using anti-DNOS1 or anti-FLAG antibodies. Im-
portantly, full-length DNOS1 protein can be immuno-
precipitated with anti-FLAG antibody from extracts of
hs-DNOS4-FLAG transgenic flies, but not of wild-type
flies (Fig. 3C). This indicates that ectopically expressed
DNOS4 can form heterodimeric complexes with endog-
enous DNOS1 in vivo and suggests that formation of
such complexes may explain the dominant negative ef-
fect of DNOS4 on NOS activity.
DNOS4 is an endogenous protein product
of the Drosophila NOS gene
We have demonstrated (Fig. 1B) that the dNOS4 tran-
script is expressed in developing and adult Drosophila.
To draw conclusions about the role of this isoform in
modulating NOS activity in the fly, it is critical to de-
termine whether dNOS4 mRNA is translated and ex-
pressed as an endogenous protein. According to the de-
duced sequence, DNOS4 protein has a unique 21-amino
acid-long peptide at its C terminus. We used this peptide
to raise a DNOS4-specific polyclonal antibody that was
further purified by affinity chromatography on the im-
mobilized recombinant antigen.
We used this DNOS4-specific antibody to examine ex-
pression of DNOS4 protein in wild-type and transgenic
flies, and in 293 cells transfected with pDNOS4 (expres-
sion plasmid encoding DNOS4 without an added FLAG
tag). The antibody recognized a protein with a mobility
of 84 kDa in extracts prepared either from heads of wild-
type or GMR-DNOS4-FLAG flies, or from 293 cells
transfected with the pDNOS4 plasmid, but not in ex-
tracts from untransfected 293 cells (Fig. 4A). The elec-
trophoretic mobility of this protein corresponds to the
calculated molecular mass for DNOS4. The same anti-
body was able also to detect the DNOS4-FLAG protein
in transgenic flies. This ectopically expressed DNOS4
protein migrates more slowly (∼86 kDa) than the wild-
type protein (84 kDa), apparently due to the presence of
two copies of the highly charged FLAG epitope at its C
terminus. These experiments demonstrate that the
DNOS4 protein is expressed in Drosophila as an endog-
enous product of the dNOS locus.
To determine whether endogenously produced
DNOS1 and DNOS4 proteins form complexes in vivo,
we performed coimmunoprecipitation experiments us-
ing DNOS1- and DNOS4-specific antibodies. We dem-
onstrated the existence of such complexes by coimmu-
noprecipitating DNOS1 from extracts of wild-type em-
bryos with DNOS4-specific antibody, and, conversely,
Figure 3. Ectopically expressed DNOS4 inhibits NOS activity
in transgenic flies and forms complexes with endogenous
DNOS1 in vivo. (A) Overexpression of DNOS4-FLAG in trans-
genic flies (hs-DNOS4-FLAG or GMR-DNOS4-FLAG) does not
affect expression of the endogenous DNOS1 protein as deter-
mined by immunoblotting using antibody against DNOS1 and
antibody against FLAG epitope (Ab for immunoblotting). (B)
NOS activity in head extracts of hs-DNOS4-FLAG (hs-DNOS4)
and GMR-DNOS4-FLAG (GMR-DNOS4) flies is decreased as
compared with that of wild-type flies. NOS activity was mea-
sured by the [3H]arginine–[3H]citrulline conversion assay. The
activity data are expressed as a percentage of the NOS activity
of the full-length enzyme alone (34,271 cpm/min/mg total pro-
tein, 100% value). The results shown are representative of three
independent experiments; all data are mean ± standard error.
Statistical significance (P < 0.05 according to Student’s t-test) is
indicated with an asterisk (*). (C) In vivo complex formation
between the endogenous DNOS1 and ectopically expressed
DNOS4-FLAG. Protein complexes were immunoprecipitated
(marked as +IP) from head extracts of transgenic (hs-DNOS4-
FLAG + IP) and wild-type (wild type + IP) flies using antibody
against FLAG epitope, and subsequently analyzed by immuno-
blotting with either DNOS1-specific or FLAG-specific antibody
(Ab for immunoblotting). A control sample (hs-DNOS4-FLAG)
was not subjected to immunoprecipitation prior to the immu-
noblotting analysis.
Stasiv et al.
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by coimmunoprecipitating DNOS4 from the same ex-
tracts using antibody to DNOS1 (Fig. 4B).
We next used DNOS1- and DNOS4-specific antibodies
to compare the expression patterns of these two DNOS
proteins during development and to examine whether
they are coexpressed in the same cells in vivo, as indi-
cated by the coimmunoprecipitation experiments. Im-
munocytochemical detection showed that both proteins
are coexpressed in a large number of cells in the embryo
(Fig. 4C–E). As a control, to test the specificity of this
detection, we used embryos that are homozygous for the
Df(2L)69F deletion, which covers a large part of the
dNOS locus, including the regions that code for the epi-
topes recognized by the anti-DNOS1 and anti-DNOS4
antibodies (M. Regulski, Y. Stasiv, T. Tully, and G. Eni-
kolopov, in prep.). We introduced a chromosome that is
marked by expression of GFP to be able to recognize the
embryos that carry a homozygous deletion of the dNOS
gene. We did not detect any specific signals when the
mutant embryos were probed with either DNOS1-spe-
cific, or DNOS4-specific antibodies (Fig. 4F). Having es-
tablished the specificity of the antibodies, we next ana-
lyzed imaginal discs of the wild-type larvae [note that
homozygotes for the Df(2L)69F deletion die in late em-
bryo] and found that in the leg, wing, and eye imaginal
discs there are highly specific patterns of expression of
DNOS1 and DNOS4, with defined areas of overlap be-
tween the two (Fig. 4G–J).
Together, these experiments demonstrate that
DNOS4 protein is produced in vivo, is expressed in a
Figure 4. DNOS4 is endogenously expressed in Drosophila and forms complexes with DNOS1. (A) DNOS4 is endogenously expressed
in Drosophila. Head protein extracts from wild-type and transgenic GMR-DNOS4-FLAG flies were analyzed by immunoblotting using
DNOS4-specific antibody (anti-DNOS4 Ab) or the preimmune serum. Control lysates from nontransfected 293 cells (293) and from
cells transfected with the pDNOS4 expression construct without FLAG tag (293-DNOS4) were probed using the same antibody or the
preimmune serum. In addition to the ectopically expressed DNOS4-FLAG protein (86 kDa), which was detected in head extracts of the
GMR-DNOS4-FLAG transgenic flies only, DNOS4-specific antibody immunoreacted with 84 kDa protein, which was expressed both
in wild-type and in transgenic flies, and had the same mobility as the DNOS4 protein transiently expressed in 293 cells (lane
293-DNOS4). (B) In vivo complex formation between the endogenous DNOS1 and DNOS4 proteins. Protein complexes were immu-
noprecipitated from wild-type embryo extracts using either DNOS1- or DNOS4-specific antibody (Ab for immunoprecipitation) and
cross-analyzed by immunoblotting with either DNOS1- or DNOS4-specific antibody (Ab for immunoblotting). The antibodies used for
immunoprecipitation and for immunoblotting are indicated. (C–J) Expression of DNOS1 (green signal) and DNOS4 (red signal) in
embryos (C–F), third-instar leg disc (G), pupae (∼3 h after puparium formation) leg disc (H), third-instar wing disc (I), and third-instar
eye disc (J). (F) Embryos carrying a homozygous deletion of the dNOS locus were used as a control for the specificity of the antibodies.
NOS regulation by dominant negative isoforms
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highly specific pattern during development, can be found
coexpressed with the full-length DNOS1 protein in
cells of the imaginal discs of the larvae and in embryo,
and forms endogenous complexes with DNOS1. This
strongly supports the notion that DNOS4 can act as a
negative regulator of DNOS1 activity in the fly.
Ectopic expression of DNOS4 increases the cell
number in the eye
NO acts as an antiproliferative factor during eye devel-
opment; pharmacological inhibition of NOS activity re-
sults in an increase in the number of cells in the om-
matidia (Kuzin et al. 1996, 2000). We asked whether
DNOS4 can act to suppress the antiproliferative action
of NO and affect cell division in the developing eye. Ec-
topic expression of DNOS4 driven by an eye-specific pro-
moter in GMR-DNOS4-FLAG flies results in a distorted
eye phenotype with visible rearrangements of the om-
matidia lattice and extra bristles (Fig. 5A). To analyze the
changes in more detail, we compared the sections of the
retina from wild-type and transgenic pupae. We found
that GMR-DNOS4-FLAG flies had extra secondary and
tertiary pigment cells as well as extra bristle cells; we did
not detect changes in the number of photoreceptor cells.
These extra cells distort the regular hexagonal shape of
the ommatidia and the general lattice pattern of the
retina (Fig. 5B).
To determine whether the increase in the number of
cells in pupae was related to increased proliferation in
the imaginal discs of larvae, we labeled the nuclei of
eye-disc cells in S phase of the cell cycle with 5-bromo-
2-deoxyuridine (BrdU). There was a 2.13-fold increase
(P < 0.001) in the number of BrdU-positive cells in imagi-
nal discs from GMR-DNOS4-FLAG flies as compared
with wild-type flies (Fig. 5C). Extra dividing cells were
localized to the region of GMR-driven transgene expres-
sion in the morphogenetic furrow and the area posterior
to it. The observed increase in the number of dividing
cells and the number of cells per ommatidium suggests
that introduction of the dominant negative dNOS4
transgene resulted in inhibition of NOS activity and sup-
pression of the antiproliferative effect of NO in the de-
veloping eye.
DNOS4 interacts with the retinoblastoma pathway
Because NO interacts with the retinoblastoma (Rb) path-
way to control cell division in the developing Drosophila
Figure 5. DNOS4 overexpression increases cell number in the adult eye. (A) Scanning electron micrographs of eyes of the wild-type
(panels a,c) and transgenic GMR-DNOS4-FLAG (panels b,d) flies. Magnification: panels a,b, 200×; panels c,d, 1000×. GMR-DNOS4-
FLAG transgenic flies have a profound eye phenotype with severe rearrangements in ommatidia lattice and appearance of extra bristles.
(B) Sections of adult retinas of the wild-type (panel a) and transgenic GMR-DNOS4-FLAG (panel b) flies. (Panels c,d) Schematic
drawing representing cell boundaries in panels a and b, respectively. Retina sections show notable changes in the GMR-DNOS4-FLAG
flies on an individual ommatidium level, such as extra bristles and primary, secondary, and tertiary pigment cells (marked by
asterisks). (C) DNOS4 overexpression in the eye imaginal disc increases number of proliferative cells. BrdU labeling of the eye-antennal
imaginal discs from late third instar wild-type (panel a) and transgenic GMR-DNOS4-FLAG (panel b) larvae using fluorescent anti-
BrdU antibody. The number of fluorescing nuclei reflects the number and distribution of cells in S phase. Increased number of
proliferating cells in the GMR-DNOS4-FLAG vs. wild-type larvae is observed in the areas posterior to the morphogenetic furrow (to
the right of the furrow; the furrow is marked by arrowhead); enlarged images of labeled cells near the equator regions of the discs are
shown in the insets.
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eye (Kuzin et al. 2000), we wanted to determine whether
DNOS4 can act to affect signaling via the Rb pathway in
the eye.
RBF is the Drosophila ortholog of mammalian Rb pro-
teins; like Rb, RBF acts as a negative regulator of cell
cycle progression (Du et al. 1996b; Du and Dyson 1999).
GMR-RBF flies that carry four copies of the RBF trans-
gene have a profound eye phenotype, due to suppression
of cell division by the elevated levels of RBF; some of the
pigment cells and bristles are missing and some omma-
tidia are fused (Fig. 6A,F; see also Du et al. 1996a; Du and
Dyson 1999). The RBF phenotype is strongly enhanced
by the ectopic overexpression of the dNOS1 transgene
(Kuzin et al. 2000). To test the effects of DNOS4 on the
action of RBF, we crossed GMR-DNOS4-FLAG flies (Fig.
6C,H) to GMR-RBF flies (Fig. 6A,F) and then backcrossed
them to GMR-RBF flies to generate flies bearing one
copy of the dNOS4 transgene along with four copies of
the RBF transgene. The eyes of the resulting hybrid flies
had an almost normal phenotype, without fused omma-
tidia, and with the usual set of bristles (Fig. 6B,G). Thus,
the effect of RBF overexpression was counteracted by
DNOS4, indicating that this inhibitor of NOS activity
counteracts RBF function in the developing eye.
In mammalian and Drosophila cells, Rb is associated
with the E2F transcription-factor complex, whose activ-
ity is required for the cells’ entry into S phase. Overex-
pression of E2F overcomes Rb-mediated G1 arrest and
induces quiescent cells to enter S phase (Du et al. 1996a;
Du and Dyson 1999). Ectopic expression of dE2F/dDP
(Drosophila orthologs of mammalian components of the
E2F complex) driven by the GMR promoter during de-
velopment results in generation of extra cells in the
adult eye (e.g., multiple extra bristles), particularly when
combined with the p35 gene, a baculoviral inhibitor of
apoptosis (Hay et al. 1994; Du et al. 1996b; Fig. 6D,I). We
crossed GMR-DNOS4-FLAG flies with GMR-dE2F/dDP/
GMR-p35 flies and found an even more pronounced eye
phenotype, with a larger eye surface, extra ommatidia,
and severe rearrangements of the ommatidia lattice (Fig.
6E,J). This indicates that DNOS4 acts to enhance the
function of E2F, consistent with the proposed role for
DNOS4 as a suppressor of the inhibitory action of NO on
cell cycle progression.
Together, these genetic data confirm that develop-
ment of the Drosophila eye depends on NO or NO-acti-
vated signaling pathways interacting with the Rb path-
way. They suggest that, by suppressing the antiprolifera-
tive action of NO, DNOS4 acts in vivo to suppress the
effect of RBF, and to enhance the effect of E2F, on cell
cycle regulation.
Discussion
NO is an important signaling molecule for diverse physi-
ological functions in Drosophila. NO regulates cell pro-
liferation in the imaginal discs of developing larvae (Ku-
zin et al. 1996) and in embryos (Wingrove and O’Farrell
1999), participates in the development of the visual sys-
tem (Gibbs and Truman 1998; Gibbs 2003), induces
vesicle release at the neuromuscular junction of larvae
(Wildemann and Bicker 1999), controls epithelial fluid
secretion by the Malpigian tubules (Dow et al. 1994; Bro-
derick et al. 2003), triggers the immune response against
bacterial pathogens (Nappi et al. 2000), induces arrest of
nuclear divisions in early embryo in response to oxygen
deprivation (DiGregorio et al. 2001), and mediates hy-
poxia-dependent exploratory behavioral responses in lar-
vae (Wingrove and O’Farrell 1999) and hypoxia-induced
stasis in embryos (Teodoro and O’Farrell 2003). This
wide range of processes mediated by NO requires tight
regulation of its production in response to different
stimuli. To accomplish this, production of NO by NOS
is controlled at multiple levels, including transcription
and translation, cofactor binding, covalent modifica-
tions, and subcellular localization.
We describe here a novel mode of regulation of NOS
activity through the synthesis of an endogenous isoform
Figure 6. Genetic interactions between DNOS4 and components of Drosophila Rb pathway. (A–C,F–H) DNOS4 rescues the RBF eye
phenotype. Scanning electron micrographs of adult eyes of indicated genotypes. Magnification: A–C, 200×; F–H, 1000×. GMR-DNOS4-
FLAG genotype is indicated as GMR-dNOS4. (D,E,I,J) Manipulation of NOS activity affects dE2F action in the developing eye.
Scanning electron micrographs of adult eyes of the indicated genotypes (all transgenes were expressed under control of the GMR
promoter). Magnification: D,E, 200×; I,J, 1000×. GMR-DNOS4-FLAG genotype is indicated as GMR-dNOS4.
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that inhibits DNOS1 in a dominant negative fashion via
heterodimerization. This regulator, DNOS4, is encoded
by an alternatively spliced version of the dNOS tran-
script. It is expressed in the imaginal discs of the devel-
oping fly in a defined pattern, with areas of conspicuous
overlap with cells that express DNOS1. DNOS4 forms
heteromeric complexes with the full-length DNOS1
polypeptide and can inhibit NOS activity both in vitro,
in cultured cells, and in vivo, in the developing fly. In the
eye imaginal disc, where DNOS1 negatively regulates
cell cycle progression, ectopic expression of DNOS4 can
block the action of DNOS1 and lead to a greater degree of
cell proliferation.
Our data further underscore the developmental role of
NO as a regulator of cell division in imaginal discs. We
show that the action of DNOS4 is reciprocal to RBF and
additive or synergistic to dE2F, thus acting to relieve the
negative effect of DNOS1 on cell proliferation during
eye-disc development. Our results support the hypoth-
esis that the DNOS family of proteins acts to modulate
the entry of cells into the S phase of the cell cycle in the
eye disc by interacting with the Rb pathway (Kuzin et al.
2000; present study). RBF or E2F proteins themselves are
potential direct targets for NO action, for example, via
S-nitrosylation of cysteine residues by endogenous NO
or NO donors (Stamler et al. 2001); intriguingly, Rb is
one of the several proteins identified in an in vivo screen
for S-nitrosylated proteins in mammalian cells (Jaffrey et
al. 2001). Furthermore, the effects of NO may also be
mediated by cGMP signaling, as guanylate cyclase is a
crucial direct target of NO in many systems (Ignarro
2000; Russwurm and Koesling 2002) and activated
cGMP-phosphodiesterases can serve as an effective
counterbalance to the NO signal (Broderick et al. 2003;
Friebe and Koesling 2003; Mullershausen et al. 2003).
Structural and kinetic analysis of NOS enzymes pro-
vides strong support for the proposed mechanism of NOS
inhibition by truncated NOS proteins. Our observations
are consistent with the proposed mechanism of NO ca-
talysis, in which electrons flow from the flavins in the
reductase domain of one subunit to the heme iron in the
oxygenase domain of the other subunit (Siddhanta et al.
1998; Panda et al. 2001, 2002; Sagami et al. 2001). An
inhibitory action of truncated products of the NOS gene
on NOS activity was demonstrated in transfected cells in
culture for the mammalian endothelial and neuronal iso-
forms as well as for Drosophila NOS (Lee et al. 1995;
Phung and Black 1999; Stasiv et al. 2001). We show here
how this feature of an endogenous truncated product of
the NOS gene can contribute to eye development in Dro-
sophila.
The DNOS1 protein carries many regions of strong
homology to the mammalian neuronal isoform (Regulski
and Tully 1995); this homology includes the part of the
oxygenase domain that is involved in dimer formation in
mammalian NOSs. However, DNOS1 lacks the N-ter-
minal PDZ domain that is involved in interactions of
nNOS with other proteins (e.g., PSD-95 and -synthro-
phin). Unlike any other known NOS, the Drosophila en-
zyme contains an almost uninterrupted stretch of Gln
residues at its N terminus (amino acids 24–52). Although
Gln-rich motifs may be involved in protein–protein in-
teractions (Perutz et al. 1994; Stott et al. 1995; Zoghbi
and Orr 2000), our data suggest that this Gln cluster is
not essential for DNOS dimer formation; the DNOSoxy
mutant that lacks the Gln-rich stretch, but retains the
“core” oxygenase domain, can still effectively complex
with the full-length Drosophila NOS and block its ac-
tivity, whereas the DNOS3 isoform, composed of 200
N-terminal DNOS residues (including the Gln-rich re-
gion, but excluding the heme-binding catalytic domain),
cannot block the enzymatic activity of DNOS1 (Stasiv et
al. 2001).
Is DNOS4 unique in its ability to regulate NOS activ-
ity? We had identified five other transcripts that encode
inactive truncated DNOS-like proteins (Stasiv et al.
2001), which we showed are capable of suppressing the
activity of DNOS1 in vitro. One of these isoforms,
dNOS7, encodes a protein identical to DNOS4, but uses
a different promoter from dNOS4. The dNOS7 mRNA is
exclusively expressed in third-instar larvae (Stasiv et al.
2001). Because we have shown that proliferation of cells
in the imaginal discs in the late third instar is controlled
by NO (Kuzin et al. 1996), it is possible that DNOS7
attenuates DNOS1 activity at this developmental stage.
Other NOS RNA isoforms are differentially expressed
during Drosophila development (Stasiv et al. 2001) and
the encoded proteins, by analogy to DNOS4, may act to
regulate NO production in vivo.
This mode of regulation that we describe for Dro-
sophila also may be involved in regulation of NOS ac-
tivity in other systems, as similar NOS transcripts have
been found in other organisms. Similarly to dNOS4,
these alternative NOS transcripts encode truncated poly-
peptides that lack the reductase domain. For instance,
exon insertions and rearrangements that introduce pre-
mature stop codons have been reported for NOS genes in
mosquito, snail, and humans (Larsson and Phillips 1998;
Luckhart and Li 2001; Korneev and O’Shea 2002).
When compared with dNOS1 RNA encoding the full-
length product, alternative NOS RNAs encoding trun-
cated proteins might be expected to be in low abundance,
perhaps due to nonsense-mediated decay (Wagner and
Lykke-Andersen 2002). Furthermore, some of these trun-
cated proteins may be subject to enhanced proteolysis
(Kaufman 2002). However, we can clearly identify endog-
enous dNOS4 and dNOS7 mRNA and the corresponding
product, DNOS4 protein, in Drosophila. This suggests
that similar truncated proteins may exist in physiologi-
cally relevant amounts in other settings. It also suggests
that this mode of regulation may be used elsewhere, in
other organisms and with other multimeric proteins or
in multisubunit signaling complexes. Truncated pro-
teins, in addition to forming inactive heteromers with
the functional isoform, may also compete for substrates
and cofactors required for catalysis, may interact with
intracellular protein partners of the active isoform, and
may change the subcellular location of such protein as-
semblies. Thus, negative control of homodimeric en-
zymes by truncated isoforms may represent an impor-
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tant regulatory mechanism used in various developmen-
tal and physiological processes.
Materials and methods
Fly stocks
To generate transgenic flies expressing DNOS4 in the develop-
ing eye, we cloned the protein-coding region of the dNOS4
cDNA fused in-frame at the 3-end to two copies of the FLAG
epitope sequence, into the blunt-ended EcoRI site of the pGMR
P-element vector (Hay et al. 1994). Germ-line transformation of
2022U flies was accomplished using standard techniques as de-
scribed (Kuzin et al. 2000). Three independent transgenic lines
P[GMR-DNOS4-FLAG;w+] were generated, one on each chro-
mosome.
To generate transgenic flies carrying the dNOS4 cDNA under
the heat-shock promoter, we cloned DNOS4-FLAG open read-
ing frame into the blunt-ended EcoRI site of the linearized
pCaSpeR-hs P-element vector. Germ-line transformation was
performed as described above. Two independent transgenic
lines P[hs-DNOS4FLAG;w+] were generated, one on the second
chromosome, and one on the third chromosome.
Stocks used for crosses GMR-RBF4 (second and third chro-
mosome; Du et al. 1996a), GMR-dE2F + GMR-dDP2 (second
chromosome; Du et al. 1996b) were gifts from N. Dyson (Massa-
chusetts General Hospital Cancer Center, Charleston, MA) and
W. Du (University of Chicago, IL). GMR-p35 (third chromo-
some; Hay et al. 1994) was a gift from B. Hay (California Insti-
tute of Technology, Pasadena, CA).
RNA analysis
A semiquantitative analysis of expression levels of various
dNOS alternative splice isoforms using total RNA samples iso-
lated from Drosophila embryos, third-instar larvae, and adult
flies was performed by RT–PCR amplification as described pre-
viously (Stasiv et al. 2001). For specific detection of the dNOS1
transcript primers from exon 12 (sense, 5-TGGCAAATCG
GAGCAGTATGC-3) and exon 15 (antisense, 5-ACCAAAG
GTCTCCTCGGTGA-3) were used. A 234-bp-long fragment of
the dNOS4 transcript was amplified using primers from exon 12
(sense, 5-TGGCAAATCGGAGCAGTATGC-3) and alterna-
tively spliced exon 14a (antisense, 5-TTAGAAGGCGGC
TGGGCCTAA-3). As a control, actin 79B RNA was amplified
using 5-CAACAATGTGCTGTCTGGC-3 (sense) and 5-
CGATCCAGACGGAGTACTTG-3 (antisense) primers. To
eliminate false-positive amplification products, negative (RT
minus) controls were amplified by PCR together with the ex-
perimental (RT plus) samples. RT–PCR products were size frac-
tionated by agarose gel electrophoresis and transferred to Hy-
bond-N+ membrane (Amersham Pharmacia Biotech). After the
transfer membranes were hybridized with [-32P]ATP oligo-
nucleotide (sense, 5-TCCTAGGGCACGCATTCAAT-3) from
exon 12 of the dNOS gene or with the actin 79B sense oligo-
nucleotide.
Tissue culture experiments
Expression constructs for the enzymatic activity assays con-
tained the protein-coding regions of dNOS1 or dNOS4 cDNAs,
each fused in-frame at the 3-end to the sequence of either two
copies of the HA epitope (pDNOS1-HA construct) or two copies
of the FLAG epitope (pDNOS4-FLAG construct) followed by a
stop codon, and were described previously (Stasiv et al. 2001). In
addition, the synthetic expression construct pDNOSoxy-FLAG,
composed of a region encoding the DNOS1 amino acids 214–
631, and fused in-frame at the 3-end to the two copies of FLAG
epitope sequence, was generated. The above plasmids were
transfected in the 293 cells as described previously (Stasiv et al.
2001). In cotransfection experiments, different molar ratios (10:
1, 3:1, 1:1) between a truncated construct (pDNOS4-FLAG or
pDNOSoxy-FLAG) over the full-length DNOS1-HA plasmid (2
µg/transfection) were used. The total amount of DNA used for
each transfection was kept constant at 25 µg by the addition of
vector DNA. Cells were collected 40 h after transfection, and
cell-free protein extracts were prepared as described (Stasiv et al.
2001). Protein concentration in tested lysates was determined
using the BCA reagent system (Pierce), and the results were
used to normalize the assays. NOS activity in lysates was ex-
amined by the [3H]L-arginine–[3H]L-citrulline conversion assay.
To compare the expression of the pDNOS1-HA construct across
the cotransfection experiments, equal amounts of protein ex-
tracts (50 µg/lane) from the transfected cells were analyzed by
SDS-PAGE. Coimmunoprecipitation experiments were per-
formed as described (Stasiv et al. 2001). For immunoblotting,
either the 12CA5 monoclonal antibody (Field et al. 1988)
against HA epitope at a final concentration of 10 µg/mL or the
M2 monoclonal antibody against FLAG epitope (Stratagene) at a
final concentration of 1 µg/mL were used. Immunoblots were
developed using the ECL system (Amersham Pharmacia Bio-
tech). For immunoprecipitation experiments, either the anti-
HA tag polyclonal antibody (Upstate Biotechnology) or the anti-
FLAG M2-Agarose affinity gel (Sigma) was used.
Drosophila protein analysis
Protein extracts from heads of wild-type or transgenic adult flies
were prepared as follows. Heads of adult flies were separated on
sieves, then homogenized at 4°C in 10 vol of extraction buffer
containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 5 µM BH4, 1 mM L-arginine, and a
standard set of protease inhibitors. Homogenates were cleared
by centrifugation for 15 min at 12,000g at 4°C. A similar pro-
cedure was used to prepare extracts from embryos. NOS activity
in Drosophila cell-free head extracts (prepared as above except
for the absence of Triton X-100 in the extraction buffer) was
measured using [3H]L-arginine–[3H]L-citrulline conversion as-
say. For the immunoprecipitation experiments, extracts were
incubated with anti-FLAG M2-Agarose affinity gel (Sigma), or
with anti-DNOS1- or DNOS4-specific antibodies (below). Im-
munoprecipitated proteins were separated by SDS-PAGE fol-
lowed by immunoblotting.
Antibodies
Anti-DNOS1 monoclonal antibody was raised against the C-
terminal 180 amino acids of the DNOS protein expressed as a
fusion protein in Escherichia coli. Monoclonal antibody was
obtained following standard procedures at the CSHL antibody
facility. Of 150 candidate hybridoma lines, 10 monoclonal lines
were selected; mAb 6/157 line was used for the experiments
described in this study.
To generate a DNOS4-specific antibody, a unique DNOS4-
specific C-terminal peptide VSTPPRKDHTELINGLGPAAF was
synthesized, conjugated to each of two carrier proteins (bovine
serum albumin and keyhole limpet hemocyanin), and used to
raise DNOS4-specific rabbit polyclonal antibody. The total im-
munoglobulin G (IgG) fraction was purified from serum of im-
munized animals using chromatography on proteinA Sepharose
4B (Sigma). The DNOS4-immunoreactive IgG subfraction was
subsequently purified by affinity chromatography as follows.
Briefly, cDNA encoding the DNOS4 C-terminal peptide was
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fused in-frame to the 3-end of the glutathione S-transferase
(GST) using the pGEX-2T bacterial expression vector (Amer-
sham Pharmacia Biotech). The resulting 31-kDa GST-DN4 fu-
sion protein was overexpressed in E. coli BL21 strain, purified by
affinity chromatography using prepacked GSTrap column (Am-
ersham Pharmacia Biotech), and then immobilized on NHS-
activated Sepharose using prepacked HiTrap column (Amer-
sham Pharmacia Biotech). The resulting GST-DN4-Sepharose
was used for affinity purification of the DNOS4-specific immu-
noglobulins. All antibody purification steps with the use of cus-
tom-made columns were performed according to a manufactur-
er’s recommendations. This purified polyclonal antibody was
used in a dilution 1:100 for the immunoprecipitation and for
detection of endogenously and ectopically expressed DNOS4 in
Drosophila cell-free extracts.
Immunocytochemistry
Embryos and imaginal discs were immunostained with mono-
clonal antibody to DNOS1 and polyclonal antibody to DNOS4
(above) using standard procedures and analyzed by confocal mi-
croscopy. Anti-DNOS1 and anti-DNOS4 antibodies were de-
tected using Alexa 488- and Alexa 633-conjugated secondary
antibodies (Molecular Probes), respectively.
Eye analysis
To identify cells in S phase, BrdU labeling of imaginal discs
from the third-instar larvae was performed as described previ-
ously (Kuzin et al. 1996). Briefly, imaginal discs were removed,
rinsed, and incubated in Schneider’s medium supplemented
with 50 µg/mL BrdU for 30 min at room temperature. The
samples were then fixed in 4% formaldehyde, treated with 1:1
mixture of heptane and formaldehyde, rinsed, depurinated by 1
M HCl, and blocked with 1% sheep serum. Incorporated BrdU
was visualized using an anti-BrdU antibody (Beckton-Dickin-
son) and fluorescein-coupled secondary antibody (Boehringer-
Mannheim). Cobalt sulfite staining of retinal sections was per-
formed as described by Wolff and Ready (1991). Scanning elec-
tron microscopy was performed at the State University of New
York-Stony Brook Imaging Center, essentially as described by
Kimmel et al. (1990).
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